Does NIVOLUMAB Cause Malignant neoplasm progression? 9,363 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9,363 reports of Malignant neoplasm progression have been filed in association with NIVOLUMAB (OPDIVO). This represents 10.7% of all adverse event reports for NIVOLUMAB.
9,363
Reports of Malignant neoplasm progression with NIVOLUMAB
10.7%
of all NIVOLUMAB reports
5,146
Deaths
4,330
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NIVOLUMAB?
Of the 9,363 reports, 5,146 (55.0%) resulted in death, 4,330 (46.2%) required hospitalization, and 797 (8.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 9,363 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
Dyspnoea (2,527)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
OSIMERTINIB (2,920)
Which NIVOLUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE